Literature DB >> 33977092

Comment on the Manuscript "Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies".

Zhaonan Li1, Dechao Jiao1, Xinwei Han1.   

Abstract

Entities:  

Year:  2021        PMID： 33977092      PMCID： PMC8077593          DOI： 10.1159/000513719

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  3 in total

1.  Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies.

Authors:  Kazuya Kariyama; Kazuhiro Nouso; Akiko Wakuta; Ayano Oonishi; Hidenori Toyoda; Toshifumi Tada; Atsushi Hiraoka; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Koichi Takaguchi; Akemi Tsutsui; Noritomo Shimada; Takashi Kumada
Journal:  Liver Cancer       Date:  2019-10-22       Impact factor: 11.740

2.  Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis.

Authors:  Piao-Piao Jin; Shi-Yi Shao; Wang-Teng Wu; Xin-Yu Zhao; Bing-Feng Huang; Qi-Han Fu; Ri-Sheng Que; Qi-Da Hu
Journal:  Jpn J Clin Oncol       Date:  2018-12-01       Impact factor: 3.019

3.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Osamu Yokosuka; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki Arai
Journal:  Gut       Date:  2019-12-04       Impact factor: 23.059
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.